Biosimilars and Biobetters
24th September 2012 — 25th September 2012

This event will look on the regulatory changes in approval of follow on biologics, rising development costs, threat from competition and marketing innovator drugs.

Join SMi at their third Biosimilars and Biobetters conference that will discuss the impact of the new regulatory guidelines and their effects on approval of follow on biologics at this exciting event. There will also be discussions on the rising development cost of biosimilars and marketing and pricing strategies, with a focus on case studies from those who are both developing and distributing follow on biologics. You cannot afford to miss this event.

Key Benefits of Attending:

• Be informed of the latest news in biosimilar pipelines
• Evaluate current and future developments in intellectual property and patent protection
• Discuss the impact of recent guidelines issued by regulatory bodies such as the FDA and EMEA
• Asses commercial and financial strategies
• Consider market access pathways and strategies
• Develop plans and methods for biosimilar and biobetter drug design and clinical testing

Hear key presentations from experts in the field:

• Sreedhar Sagi, Risk Management Compliance Officer Biopharmaceuticals Development, Sandoz
• Ezogelin Oflazoglu, Senior Director and Senior Project Leader, MBV Biologics PPM, Merck Bioventures
• Laura McKinley, Director Worldwide Regulatory Strategy, Pfizer
• Richard DiCicco, Chairman, Harvest Moon Pharmaceuticals USA, Inc
• Anne Dollard, Chief Patent Counsel, Deputy General Counsel, Takeda Pharmaceuticals
• Sandy Eisen, Chief Medical Officer, former CMO, Frontline Pharma Consulting, Teva Pharmaceuticals
• David Szymkowski, Senior Director, Research, Biotherapeutics, Xencor, Inc
• Heinz Hänel, Director, Diabetes Division R&D Projects, Sanofi
• Andrew Rankin, Head of Clinical Development, Teva Pharmaceuticals
 

Plus an interactive half-day post-conference workshop
Wednesday 26th September 2012, Copthorne Tara Hotel, London

A critical review of US and EU legal framework for biosimilars products including practical examples for strategic development
9.00am – 12.30pm
In association with Arnold and Porter LLP

Suggested Attendees

Chief Executives, Executive Directors, Vice Presidents, Heads and Team Leaders from: * Intellectual Property * Business Development * Licensing * Manufacturing * APIs * Drug and Safety Assessment

Expected Number of Attendees

NA

View Conference Website: Biosimilars and Biobetters

Price of Attendance

£1798

Brochure

View Event Brochure

Location

Scarsdale Place
London
United Kingdom
W8 5SR